Group 1 - Praxis Precision Medicines Inc. shares surged 24.81% in pre-market trading, reaching $237.10 after closing at $189.97, which was a 2.05% increase in the previous session [1][2] - The company reported positive results from the registrational cohort of its EMBOLD study, evaluating relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, with an FDA meeting scheduled to review the data [2][3] - There are currently no approved treatment options for SCN2A and SCN8A DEEs, which are conditions with high mortality rates due to severe seizure burdens [3] Group 2 - Praxis completed a pre-NDA meeting with the FDA for ulixacaltamide, an essential tremor treatment, and plans to submit the NDA in early 2026 [4] - The stock has increased by 349.53% over the past six months, with a market capitalization of $4.75 billion, trading between $26.70 and $206.36 in the past 52 weeks [5] - The stock shows strong momentum in the 98th percentile, indicating a positive price trend across all time frames [5]